These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 19300039)
1. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer. Papatheofanis FJ; Smith C; Najib M Am J Ther; 2009; 16(2):127-32. PubMed ID: 19300039 [TBL] [Abstract][Full Text] [Related]
2. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302 [TBL] [Abstract][Full Text] [Related]
3. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study. Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320 [TBL] [Abstract][Full Text] [Related]
4. Bone marrow recovery following use of systemic (153)Sm-lexidronam and (89)Sr-chloride for bone pain palliation after myelosuppressive therapy. Papatheofanis FJ; Najib MM Int J Radiat Biol; 2009 May; 85(5):448-53. PubMed ID: 19437245 [TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Dolezal J; Vizda J; Odrazka K Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764 [TBL] [Abstract][Full Text] [Related]
7. Samarium-153-lexidronam therapy for metastatic bone pain. Ribera H J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):80-1; discussion 81-2. PubMed ID: 23527672 [TBL] [Abstract][Full Text] [Related]
8. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005). Barnard SM; Zuber RM; Moore AS J Am Vet Med Assoc; 2007 Jun; 230(12):1877-81. PubMed ID: 17571994 [TBL] [Abstract][Full Text] [Related]
9. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Turner SL; Gruenewald S; Spry N; Gebski V; Br J Cancer; 2001 Feb; 84(3):297-302. PubMed ID: 11161391 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Menda Y; Bushnell DL; Williams RD; Miller S; Thomas MO Clin Nucl Med; 2000 Sep; 25(9):698-700. PubMed ID: 10983757 [TBL] [Abstract][Full Text] [Related]
11. Strontium 89 therapy for the palliation of pain due to osseous metastases. Robinson RG; Preston DF; Schiefelbein M; Baxter KG JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Liepe K; Kotzerke J Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384 [TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal]. Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329 [TBL] [Abstract][Full Text] [Related]
14. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Baczyk M; Czepczyński R; Milecki P; Pisarek M; Oleksa R; Sowiński J Nucl Med Commun; 2007 Apr; 28(4):245-50. PubMed ID: 17325585 [TBL] [Abstract][Full Text] [Related]
16. Use of strong opioids in advanced cancer pain: a randomized trial. Marinangeli F; Ciccozzi A; Leonardis M; Aloisio L; Mazzei A; Paladini A; Porzio G; Marchetti P; Varrassi G J Pain Symptom Manage; 2004 May; 27(5):409-16. PubMed ID: 15120769 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120 [TBL] [Abstract][Full Text] [Related]
18. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. Heidenreich A; Hofmann R; Engelmann UH J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382 [TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of percutaneous vertebroplasty versus optimal medical management for the relief of pain and disability in acute osteoporotic vertebral compression fractures. Farrokhi MR; Alibai E; Maghami Z J Neurosurg Spine; 2011 May; 14(5):561-9. PubMed ID: 21375382 [TBL] [Abstract][Full Text] [Related]
20. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate]. Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]